直接口服抗凝药与华法林在房颤患者中的患者水平网络荟萃分析:按年龄和性别进行交互检验
结果显示,与华法林相比,标准剂量DOAC显著降低卒中或系统性栓塞、死亡和颅内出血风险,但大出血风险无统计学差异;低剂量DOAC不增加卒中或系统性栓塞风险,且降低颅内出血、死亡和大出血风险。
要点
- 标准剂量DOAC较华法林显著降低卒中或系统性栓塞(HR 0.81)、死亡(HR 0.92)和颅内出血(HR 0.45)。
- 低剂量DOAC较华法林不增加卒中或系统性栓塞风险(HR 1.06),且降低颅内出血(HR 0.28)、死亡(HR 0.90)和大出血(HR 0.63)。
- 标准剂量和低剂量DOAC versus 华法林对卒中或系统性栓塞和死亡的治疗效应在年龄和性别间一致。
核心结论
- 与华法林相比,DOAC在房颤患者中具有更有利的疗效和安全性。
研究设计与样本
- 采用分层Cox模型联合随机效应比较标准剂量DOAC、低剂量DOAC与华法林。
主要发现
- 标准剂量DOAC vs 华法林:卒中或系统性栓塞HR 0.81(95%CI 0.74-0.89),死亡HR 0.92(95%CI 0.87-0.97),颅内出血HR 0.45(95%CI 0.37-0.56),大出血HR 0.86(95%CI 0.74-1.01,无统计学差异)。
- 低剂量DOAC vs 华法林:卒中或系统性栓塞HR 1.06(95%CI 0.95-1.19,无统计学差异),颅内出血HR 0.28(95%CI 0.21-0.37),死亡HR 0.90(95%CI 0.83-0.97),大出血HR 0.63(95%CI 0.45-0.88)。
- 标准剂量DOAC vs 华法林在无维生素K拮抗剂使用史患者中更受青睐(P=0.01),在较低肌酐清除率患者中趋向更优(P=0.09)。
- 标准剂量DOAC vs 华法林在大出血方面,较低体重患者中更受青睐(P=0.02)。
- 连续协变量分析中,较年轻患者从标准剂量DOAC(交互P=0.02)和低剂量DOAC(交互P=0.01)vs 华法林中获益更大。
临床怎么用
- 房颤患者卒中预防可优先考虑DOAC而非华法林。
- 标准剂量DOAC适用于大多数患者,尤其无维生素K拮抗剂使用史或较低肌酐清除率者可能获益更多。
- 低剂量DOAC可作为需要降低出血风险患者的选择,但需注意其卒中或系统性栓塞风险与华法林无统计学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. METHODS: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. RESULTS: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74-0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87-0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37-0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74-1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95-1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21-0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83-0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45-0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use (P=0.01) and lower creatinine clearance (P=0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight (P=0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P=0.02) and lower-dose DOACs (interaction P=0.01) versus warfarin. CONCLUSIONS: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.
引用
- Carnicelli, Hong, Connolly, et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022. PMID: 34985309. doi:10.1161/CIRCULATIONAHA.121.056355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。